Last reviewed · How we verify

LAROPIPRANT — Competitive Intelligence Brief

LAROPIPRANT (LAROPIPRANT) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: laropiprant. Area: Metabolic.

marketed laropiprant Prostaglandin D2 receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

LAROPIPRANT (LAROPIPRANT).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LAROPIPRANT TARGET LAROPIPRANT marketed laropiprant Prostaglandin D2 receptor
Comparator: niacin + laropiprant Comparator: niacin + laropiprant Merck Sharp & Dohme LLC phase 3 Lipid-modifying agent combination Niacin: GPR109A (hydroxycarboxylic acid receptor 2); Laropiprant: DP1 (prostaglandin D2 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (laropiprant class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LAROPIPRANT — Competitive Intelligence Brief. https://druglandscape.com/ci/laropiprant. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: